Entera Bio (NASDAQ:ENTX) Trading Down 0.9% – Here’s What Happened

by · The Cerbat Gem

Entera Bio Ltd. (NASDAQ:ENTX – Get Free Report) shares dropped 0.9% on Monday . The company traded as low as $2.10 and last traded at $2.13. Approximately 24,561 shares traded hands during mid-day trading, a decline of 68% from the average daily volume of 76,335 shares. The stock had previously closed at $2.15.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ENTX. HC Wainwright raised shares of Entera Bio to a “strong-buy” rating in a research report on Monday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

View Our Latest Stock Report on Entera Bio

Entera Bio Trading Down 0.9%

The firm has a market capitalization of $97.68 million, a P/E ratio of -8.52 and a beta of 1.71. The stock’s 50-day simple moving average is $2.46 and its 200-day simple moving average is $2.12.

Entera Bio (NASDAQ:ENTX – Get Free Report) last announced its earnings results on Friday, November 14th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. Entera Bio had a negative return on equity of 67.56% and a negative net margin of 4,525.11%. On average, equities research analysts expect that Entera Bio Ltd. will post -0.28 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. HighTower Advisors LLC raised its stake in shares of Entera Bio by 53.3% during the 1st quarter. HighTower Advisors LLC now owns 18,140 shares of the company’s stock worth $31,000 after purchasing an additional 6,310 shares during the period. Parkman Healthcare Partners LLC grew its position in Entera Bio by 6.3% during the first quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company’s stock valued at $747,000 after buying an additional 25,900 shares during the period. Bessemer Group Inc. purchased a new stake in Entera Bio during the second quarter worth about $268,000. Finally, Citadel Advisors LLC raised its position in Entera Bio by 243.0% in the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after acquiring an additional 28,322 shares during the period. Institutional investors own 14.11% of the company’s stock.

Entera Bio Company Profile

(Get Free Report)

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.

Featured Stories